Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Role of Chloroquine for Malaria Elimination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male individuals~* P. falciparum infection detected by microscopy (Minimum 250 parasites/microliter; Maximum 10.000parasites/microliter)~* Ability to swallow oral medication~* Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and~* Informed consent from the participant individual~Exclusion Criteria:~* Age \<18 years~* Female individuals~* Axillary temperature \>=37.5ºC~* Presence of any other co-existing clinical condition that in the opinion of the recruiting physician would not allow the individual to be considered a healthy asymptomatic carrier~* Regular medication which may interfere with antimalarial efficacy or antimalarial pharmacokinetics, such as Cotrimoxazole~* History of hypersensitivity reactions or contraindications to CQ~* Known HIV positive patients in treatment with antiretrovirals

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chloroquine (Type: EXPERIMENTAL): Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain.

Based on this trial design, predict the completion outcome and termination type (if applicable).